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Background: Thymidine kinase 1 (TK1) is a cellular enzyme involved in DNA precursor synthesis, and its activity has
been used as a proliferation marker for monitoring malignant diseases. Here, for the first time, we evaluated both
TK1 activity and protein levels in sera from patients with different malignancies.
Methods: Serum samples from patients with myelodysplastic syndrome (MDS, n = 22), breast cancer (n = 42),
prostate cancer (n = 47) and blood donors (n = 30) were analyzed for TK1 protein and activity levels, using a
serum TK1 (STK1) protein assay based on antibodies and an activity assay that measured [3H]-deoxythymidine
(dThd) phosphorylation. The molecular forms of TK1 in sera from some of these patients were analyzed using
size-exclusion chromatography.
Results: Mean STK1 activities in sera from MDS, breast and prostate cancer were 11 ± 17.5, 6.7 ± 19 and 1.8 ± 1.4
pmol/min/mL, differing significantly from blood donors (mean ± standard deviation (SD) = 1.1 ± 0.9 pmol/min/mL).
Serum TK1 protein (25 kDa polypeptide) levels were also significantly higher in MDS, breast, prostate cancer compared
to blood donors (mean ± SD = 19 ± 9, 22 ± 11, 20 ± 12, and 5 ± 3.5 ng/mL, respectively). The STK1 specific activities of
sera from patients with MDS and blood donors were significantly higher when compared with activities in sera
from breast and prostate cancer patients. Size-exclusion analysis of sera from breast and prostate cancer showed
that the detected active TK1 was primarily a high molecular weight complex, similar to the forms found in sera
from MDS patients and blood donors. However, Western blotting demonstrated high TK1 25 kDa protein levels in
fractions lacking TK1 activity in sera from cases with breast and prostate cancer.
Conclusions: These results demonstrate that there are differences in the specific activities and the subunit
compositions of STK1 in hematological malignancies compared with breast and prostate cancer. This fact has
several important implications for the use of STK1 as a tumor biomarker. One is that STK1 protein assays may
differentiate early-stage tumor development in breast and prostate cancer more effectively than STK1 activity assays.
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Tumors are primarily characterized by uncontrolled
cell proliferation, and the proliferative activity of cancer
cells correlates with the aggressiveness of the disease.
Prognostic markers that can measure tumor-cell prolif-
eration are clinically valuable because they may im-
prove the early detection and treatment monitoring of
tumor diseases [1]. Thymidine kinase 1 (TK1) is one of
these proliferation biomarkers and is involved in the
salvage pathway of DNA precursor synthesis. TK1 cata-
lyzes the conversion of thymidine to deoxythymidine
monophosphate (dTMP), which is further phosphory-
lated to di (dTDP) and triphosphates (dTTP) prior to be-
ing incorporated into DNA [2]. TK1 expression is S-phase
dependent, and high levels of TK1 have been noted in
proliferating and malignant cells [3,4]. TK1 activity in-
creases in late G1 and peaks in the S phase and then
decreases during the M phase due to the action of a
specific degradation pathway [5]. STK1 (serum TK1)
activity may be measured using different assays, e.g.,
TK-REA [6], TK Liaison [7], the Divitum assay [8] and
the [3H]-deoxythymidine (dThd) phosphorylation assay
[9]. Recent study showed that [3H]-dThd phosphorylation
correlates well with the TK-Liasion assay (r = 0.96) and
TK-REA (r = 0.92) [9]. It is well established that STK1 ac-
tivity may be used as a prognostic marker in cases of
leukemia and lymphomas [10-13] and to some extent in
cases of breast cancer [14-16].
The development of anti-human TK1 antibodies
[17] has extended the application of serum TK1 pro-
tein determination for many different tumor diseases,
and several clinical studies have demonstrated in-
creased serum TK1 protein levels in solid-tumor dis-
eases [18-23]. In general, TK1 protein assays showed
higher sensitivity than STK1 activity measurements in
cases with solid-tumor diseases, both in humans [24]
and dogs [25].
The concentration of STK1 correlates with diagnosis
and treatment outcome in breast [26-28], lung and gas-
tric carcinomas [29,30]. However, STK1 activities do
not show this pattern. A recent study demonstrated
that TK1-ELISA is more sensitive for early-stage detec-
tion of lung cancer compared with STK1 activity assays
[31]. In this study, we measured both serum TK1 activ-
ity and TK1-25-kDa protein levels in MDS, breast and
prostate cancer patients. The ability of the STK1 activ-
ity assays and STK1 protein assays to discriminate
malignant samples from blood donors was tested using
ROC analysis. The specific activities of serum TK1 pro-
tein in the sera from these patients and blood donors
were determined. The molecular forms of TK1 in some
of these sera samples were also investigated using size-
exclusion chromatography, and important differences
were revealed.Methods
Serum samples
Serum samples from MDS (n = 22), breast (n = 42) and
prostate cancer (n = 47) patients were purchased from
Biotheme Research Solutions Inc., Florida, USA (Sam-
ples were collected as de-identified diagnostic remain-
ders excempt from Title 46, Title 21 and HIPAA IRB/
Consent requirements. Serum samples were collected
under an IRB approved protocol or collected as consented
donor samples from FDA licensed/registered facility fol-
lowing GMPs. They followed necessary procedures for
obtaining the informed consent of donors). Information
on the clinical staging (TNM), histological classification
for breast cancer patients and the Gleason Score (GS) in
cases with prostate cancer were received from Biotheme
and are shown in the supplementary tables. Serum sam-
ples from blood donors (n = 30) were purchased from
ProMedDx, Norton, MA, USA, and they were free from
any viral infections or illnesses. The mean age was 27
years (range 17-59 years) for the blood donors, MDS
patients showed a mean age of 76 years (range 61-89),
whereas the mean age was 58 years (range 43-86 years)
for patients with breast cancer. In cases with prostate
cancer, the mean age was 70 years (range 33-91 years).
Samples were stored at -20°C until analysis. The study
comprised 141 samples including sera from blood donors
(n = 30) and patients with MDS (n = 22), breast cancer (n =
42) or prostate cancer (n = 47).TK1 antibodies, chicken polyclonal and mouse
monoclonal XPA 210 antibodies
Both monoclonal and polyclonal antibodies used in this
study were raised against the C- terminal region of TK1.
A 31-amino acid peptide (GQPAG PDNKE NCPVP
GKPGE AVAAR KLFAPQ, 194-225) was used the anti-
gen for the production of chicken immunoglobulin (IgY)
antibodies, and they were purified by affinity chromatog-
raphy as described previously [17]. Mouse monoclonal
antibody (XPA 210) against the same peptide was pre-
pared as previously described [4]. These antibodies were
supplied by Arocell AB (Uppsala, Sweden).Serum thymidine kinase activity assay
STK1 activities in the serum samples were determined
using an optimized [3H]-dThd phosphorylation assay as
described previously [9]. In brief, 10 μL of serum was in-
cubated with a reaction buffer containing 20 mM Tris/
HCl, pH 7.6, 2 mM dithiothreitol (DTT), 5 mM sodium
fluoride (NaF), 5 mM MgCl2, 5 mM adenosine triphos-
phate (ATP) and 5 μM [-3H]-dThd (20 Ci/ml, PerkinElmer,
Boston, MA, USA). The reaction mixture was incubated at
37°C for 1 h. The radioactivity in the reaction products was
determined as described previously [9]. Thymidine kinase
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Immunoaffinity Sepharose preparations
The XPA 210 antibody was covalently coupled to
cyanogen bromide (CNBr)-activated Sepharose 4 fast
flow (GE HealthCare, Uppsala, Sweden) as described
previously [25] and as shown in the supplementary in-
formation (Figure 1). The antibody-coupled Sepharose
was stored in Tris-buffered saline (TBS) containing
0.01% NaN3 1:1 at 4°C.
Isolation of thymidine kinase 1 (TK1) using anti-TK1
antibody-coupled Sepharose
Recombinant human TK1 (0.3-2.8 ng), 50 μL of serum
samples and 300 μL of FPLC fractions from serum
samples were diluted with 180μL of TBS, pH 7.6, and
then incubated with anti-human TK1 antibody-coupled
Sepharose (70 μL of a 1:1 V/V mixture of antibody-
Sepharose and TBS). The samples were then agitated at
4°C for 4 h followed by centrifugation for 1 min at
13,000 revolutions per min (RPM). The antibody-
coupled Sepharose was washed twice with TBS, once
with TBS-T and one more time with TBS. Then, 30 μL
of sample buffer (containing Tris-HCl, pH 6.8, 0.5 M;
glycerol, 20% (w/v) SDS, 10%; bromophenol blue 0.1%;
and DTT,10 mM) was added to the Sepharose and the
solution incubated at room temperature for 20 min to
elute bound serum proteins. These eluted complex pro-
teins were heated at 95°C for 5 min and analyzed using
12% SDS-PAGE and transferred to PVDF membranes
(GE-Healthcare) using a semi-dry transfer method.Figure 1 Immunoaffinity analysis of human recombinant TK1 and ser
of purified recombinant human TK1 and the 26 kDa band relative intensity
immunoaffinity/Western blotting analysis of sera from blood donors, (C) MAfter blocking with 5% BSA in TBS-Tween for 1 hr,
the bound proteins were detected using a chicken anti-
TK1 antibody followed by incubation with a HRP-
conjugated anti-chicken IgY antibody. The peroxidase
reaction was detected using ECL (GE Healthcare,
Uppsala, Sweden). Films were exposed for 2 min to ob-
tain detectable band intensities for serum and recom-
binant TK1 controls. Densitometry scanning of these
films was performed using an Epson perfection V
scanner. The TK1 polypeptide band corresponding to
25 kDa was quantified using image analysis software
(Image Gauge G3.3, Science Lab, Fuji Photo Film Co.,
Ltd., Tokyo, Japan). A standard curve was created by
measuring the intensities of different amounts of re-
combinant TK1.Size-exclusion chromatography
Size-exclusion chromatography was performed as de-
scribed previously [32,33]. In brief, 200 μL of sera from
MDS, breast, prostate cancer patients and blood donors
was diluted to 1:1 in a buffer containing 0.01 M Hepes,
0.15 M NH4Cl and 0.02% NaN3 prior to injection into
a Superose 12 column (1.0 × 30 cm, GE Health care,
Sweden). The column was equilibrated with the same
buffer and eluted at flow rate of 0.4 mL/min. Twenty
four fractions (0.4 mL) were collected, and the TK1
protein content in the fractions determined and com-
pared with standards of different molecular weights:
α2-macroglobulin (720 kDa), β amylase (200 kDa), bo-
vine serum albumin (66 kDa), ova albumin (45 kDa)
and horse myosin (17 kDa).um TK1. (A) Results from the immunoaffinity/Western blotting analysis
(arbitrary units, A.U.) used as a standard. (B) Examples of results of the
DS patients, (D) breast cancer, (E) or prostate cancer patients.
Table 1 Mean serum thymidine kinase 1 (STK1) protein,
STK1 activity levels and correlation between STK1





Mean ± SD (M) Mean ± SD (M)
Tumor type N rs* P
Myeloid dysplastic 22 19 ± 9.0 (19) 11 ± 17.5 (3) 0.63 0.0015
Syndrome (MDS)
Breast cancer 42 22 ± 11 (21) 6.7 ± 18.8 (1.8) 0.41 0.0077
Prostate cancer 47 20 ± 12 (22) 1.8 ± 1.4 (1.3) 0.45 0.0015
Healthy 30 5 ± 3.5 (4) 1.1 ± 0.6 (0.9) 0.49 0.0056
*Spearman’s correlation coefficient.
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Distributions of STK1 activity and protein levels in
healthy, MDS, breast and prostate cancer sera were eval-
uated for normality using the D’Agostino and Pearson
omnibus normality test. Serum TK1 activities in differ-
ent groups showed non-Gaussian distributions, whereas
STK1 protein levels followed Gaussian distributions.
Consequently, the Mann-Whitney U test was used for
comparing STK1 activities between groups, and un-
paired t-tests were used to compare differences in STK1
protein levels between groups. One way ANOVA
followed by Turkey’s multiple comparison post-test to
compare TK1 protein levels and Dunn’s Multiple
Comparison post-test was used to compare TK1 activity
across multiple groups. Spearman’s correlation coeffi-
cient (rs) was used to determine correlations between
different parameters. All statistical analyses were
performed using GraphPad Prism 5.0 (GraphPad Soft-
ware, La Jolla, CA, USA). Receiver operating characteris-
tic (ROC) curves were constructed to evaluate the
performance of the [3H]-dThd phosphorylation assay
and the immunoaffinity assay results in different groups.
Statistical significance was achieved when P < 0.05.
Results
Serum sample STK1 activities and STK1 protein levels
Immunoaffinity Western blotting assays were established
using different concentrations (0.3-2.8 ng) of human re-
combinant TK1 as standards (Figure 1A). Examples of
determinations of the TK1-25-kDa protein bands in sera
from blood donors and patients with MDS, breast and
prostate cancer are shown in Figure 1B-E, respectively.
Protein levels were determined using a recombinant
TK1 standard curve. Blots of the remaining serum sam-
ples may be found in Additional file 1: Figures S2, S3
and S4. Some cross-reacting bands were detected in the
high-molecular-weight region; however, the majority was
due to cross reactivity originating from the secondary
anti-chicken IgY antibodies. No cross-reacting bands
were detected at 25 kDa, which was also demonstrated
in competition experiments where the anti-TK1 anti-
body was mixed with the antigen peptide (at a 1:1 ratio)
(data not shown). These results strongly suggest that the
immunoaffinity assay provides an accurate measurement
of STK1 protein levels in the samples.
The mean serum TK1 activities and TK1 protein levels
for the blood donors and the different patient groups are
shown in Table 1 and in Additional file 2: Tables S1-S4
and are described separately below.
Blood donors
The mean STK1 activity values ranged from 0.5-3.2
pmol/min/mL (mean ± SD = 1.1 ± 0.6 and median = 1.0).
Immunoaffinity/Western blotting analyses revealed faintTK1-25-kDa protein bands in the majority of the donor
sera; however, approximately 30% were below the detec-
tion limit (Figure 1B). Thus, STK1 protein levels ranged
from undetectable to 13 ng/mL (mean ± SD = 5 ± 3.5 and
median = 4.0). A significant correlation was observed be-
tween STK1 activity and STK1 protein levels in the sam-
ples from blood donors (rs = 0.49, P = 0.005). In this
experimental group, there were no significant changes in
STK1 activity or STK1 protein levels with age.
MDS patients
The mean ± SD STK1 activity in MDS patient sera was
11 ± 17.5, with a range of 1-62 pmol/min/mL, which
was significantly higher compared with blood-donor
sera (P < 0.0001, Figure 2A). Western blotting analysis
revealed TK1 protein levels with a range of 3-36 ng/mL
(mean ± SD= 19 ± 9 and median = 19), which was signifi-
cantly higher than in sera from blood donors (P < 0.0001,
Figure 2B). No significant correlation was found between
age and STK1 activity or STK1 protein levels. ROC curve
analysis revealed that the TK1 activity assay showed an
area under the curve (AUC) of 0.93, (P < 0.0001; 95%
confidence interval (CI) 0.86-0.99), with a cutoff value
of 3.1 pmol/min/mL, a sensitivity of 0.48 and specificity
of 0.96 (Figure 2C). The TK1 protein assay showed an
AUC of 0.93, (P < 0.0001; 95% CI 0.85-0.99), a cutoff
value of 12.5 ng/mL, a sensitivity of 0.63 and a specifi-
city of 0.96 (Figure 2D).
Breast cancer
STK1 activity levels in breast cancer sera were in the
range of 0.5-118 pmol/min/mL (mean ± SD = 6.7 ± 19
and median = 1.8) and were significantly higher than
levels in sera from blood donors (Figure 3A). Immunoaf-
finity/Western blotting analysis of sera from breast can-
cer patients showed high STK1 protein levels compared
with blood donors, and they ranged up to 45 ng/mL
(mean ± SD = 21 ± 10 and median = 21; Figure 3B). A sig-
nificant negative correlation (rs = -0.41, P = 0.0057) was
Figure 2 TK1 activity and protein levels in sera from MDS patients and blood donors. (A) STK1 activity in sera from blood donors (•) and
MDS patients (■). (B) Concentrations of STK1 in sera from blood donors (•) and MDS patients (■). Error bars denote SDs. (C) The receiver
operating characteristic (ROC) curve of STK1 activities for discrimination between blood donors and MDS patients. (D) ROC curve analysis of STK1
protein levels in blood donors and MDS patients.
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however, STK1 protein levels did not show this correl-
ation in this patient group. Serum samples were classi-
fied into two groups based on tumor size (T), i.e., early
stage (TiS + T1) and late stage (T2 + T3). STK1 activ-
ities were significantly higher in late-stage (T2 + T3)
compared with blood donors (P < 0.0001) and early-
stage (TiS + T1) patients (P = 0.0273). However, STK1
activity levels in early-stage patients (TiS + T1) were
not significantly different compared with blood donors
(P = 0.283) (Figure 3C), whereas STK1 protein levels
from early (P = 0.0001) and late stages of tumor pro-
gression (P < 0.0001) were significantly different from
blood donors (Figure 3D). These samples were further
classified based on histological examinations [34] as ductal
carcinoma in situ (DCIS), invasive ductal carcinoma (ID)
and invasive ductal/ lobular carcinoma (ID/L). STK1 ac-
tivity levels in invasive carcinoma (ID + ID/L) were sig-
nificantly higher than in blood donors (P = 0.002) but
this increase was not present in non-invasive (DCIS),
which is considered an early stage of tumor develop-
ment (P = 0.054) (Figure 3E). STK1 protein levels in inva-
sive carcinomas (P < 0.0001) and DCIS were significantlyhigher than in blood donors (P = 0.0014) (Figure 3F).
Furthermore, ROC curve analysis showed that the
TK1 activity assay had an AUC of 0.77 (P < 0.0001,
95% CI = 0.66–0.87), with a cutoff value of 3.1 pmol/
min/mL, a sensitivity of 0.26 and a specificity of 0.96
(Figure 3G). In the case of the TK1 protein assay, the
AUC was 0.97 (P < 0.0001, 95% CI 0.90-0.99). At the
optimal cutoff value of 12.5 ng/mL, the true positive
rate was 79%, whereas the false-positive rate was 4%
(Figure 3H). These results indicate that the STK1 pro-
tein assay may differentiate early-stage tumors more
efficiently compared with the STK1 activity assay.
Prostate cancer
In prostate cancer sera, STK1 activities ranged from
0.6-7 pmol/min/mL (mean ± SD = 1.8 ± 1.4 and me-
dian = 1.3), and they showed significantly higher STK1
activity than blood donors (Figure 4A). The mean
STK1 protein levels in sera from prostate cancer pa-
tients (mean ± SD = 20 ± 12 ng/mL and median = 22)
was significantly higher compared with levels in sera from
blood donors (Figure 4B). Based on the modified Gleason
score (GS) grades [35], prostate serum samples were
Figure 3 TK1 activity and protein levels in breast cancer patients and blood donors. (A) STK1 activity distributions in sera from blood donors (•)
and patients with breast cancer (■). (B) STK1 protein levels in sera from blood donors (•) and patients with breast cancer (■).
(C) Comparison of STK1 activities in sera from blood donors (•) and early-stage (TiS + T1; ■) and late-stage (T2 + T3;▲) breast cancer patients.
(D) Comparison of STK1 protein levels in sera from blood donors (•) and early-stage (TiS + T1; ■) and late stage (T2 + T3;▲) breast cancer patients.
(E) Comparison of STK1 activities in blood donors (•) and non-invasive (DCIS; ■) and invasive (ID + ID/L;▲) breast cancer patients.
(F) Comparison of STK1 protein levels in blood donors (•) and non-invasive (DCIS; ■) and invasive (ID + ID/L) breast cancer patients (▲). The error bars
denote standard deviations (SDs). (G) Receiver operating characteristic (ROC) curve of STK1 activity in serum samples from breast cancer patients and
from blood donors. (H) ROC curve analysis of STK1 protein levels in sera from blood donors and breast cancer patients.
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and moderately/poorly differentiated (GS7 + 8) cancer.
The STK1 activity assay discriminated moderately/poorly
differentiated from well-differentiated cancer (P = 0.0094)
and from blood donors (P = 0.0009) but no significant dif-
ference was observed between well-differentiated cancer
and blood donors (P > 0.99) (Figure 4C). In contrast, the
STK1 protein assay significantly discriminated well-
differentiated cancer from blood donors (P = 0.0002)
(Figure 4D). These results indicate that the STK1 protein
assay, but not the STK1 activity assay, was capable of de-
tecting well-differentiated cancer prior to its progression
to poorly differentiated cancer. ROC curve analysisdemonstrated that the STK1 activity assay had a sensi-
tivity of 0.15 and a specificity of 0.96 with an AUC of
0.69 (P = 0.0042, 95% confidence interval (CI) 0.57–0.81;
Figure 4E) at the optimal cutoff value of 2.9 pmol/min/
mL. The STK1 protein assay showed an AUC of 0.88 with
a sensitivity of 0.64 and a specificity 0.96 (P < 0.0001, 95%
confidence interval (CI) 0.81–0.95) at a cut-off value of
12.5 ng/mL (Figure 4F).
Serum TK1 activity values (Figure 5A) and STK1 pro-
tein levels (Figure 5B) in healthy, MDS, breast and pros-
tate cancer were compared, and no significant
differences were found in mean STK1 protein levels be-
tween MDS, breast and prostate cancer. However,
Figure 4 TK1 activity and protein levels in sera from prostate cancer patients and blood donors. (A) STK1 activity in sera from blood donors
(•) and prostate cancer patients (■). (B) Concentrations of STK1 in sera from blood donors (•) and prostate cancer patients (■).
(C) Comparison of STK1 activity in sera from blood donors (•) and well-differentiated (GS5 + 6; ■) and moderately/poorly differentiated (GS7 + 8;▲)
prostate cancer patients. (D) Comparison of STK1 protein levels in blood donors (•) and well-differentiated (GS5 + 6; ■) and moderately/poorly differentiated
(GS7 + 8;▲) prostate cancer patients. The error bars denote standard deviations (SDs). (E) Receiver operating characteristic (ROC) curve of STK1
activities in sera from prostate cancer patients compared with sera from blood donors. (F) A similar ROC curve analysis of STK1 protein assay
results in sera from blood donors and prostate cancer patients.
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ity and STK1 protein levels in MDS, breast and prostate
cancer sera (rs = 0.63, P = 0.0015, rs = 0.41, P = 0.0077
and rs = 0.45, P = 0.0015; Table 1).
The specific activity of TK1 in sera from different groups
In this study, the specific activity of STK1, i.e., the nmol
dTMP formed per min per mg of STK of 25 kDa pro-
tein, was determined using a significant number of clin-
ical samples. The specific activities are based on direct
[3H]-dThd phosphorylation activity measurements and
on determinations of STK1 protein levels using immu-
noaffinity/Western blotting analyses. The results are
shown in Table 2 and may be summarized as follows: the
specific activity of STK1 (25 kDa) protein (mean ± SD) in
sera from blood donors was 133 ± 67 nmol/min/mg, in
sera from MDS patients, it was 137 ± 112, in breast
cancer sera, it was 61 ± 53 and in prostate cancer sera,
it was 52 ± 35 nmol/min/mg. Specific activities are
compared in Figure 5C, and the highest STK1 specific
activities were noted in three sera from MDS patients
(sample no: 10, 15 and 20, Additional file 2: Table S2)and in two sera from breast-cancer patients (sample no:
9 and 37, Additional file 2: Table S3). Because these
samples showed very high values, they were regarded as
outliers and were excluded from the mean of the
groups. The mean specific activity of TK1 in sera from
blood donors and MDS patients was significantly
higher (approx. 2-fold) compared with activities in sera
from breast and prostate cancer patients (Table 2).
Molecular forms of serum TK1 in patients with different
malignancies
A serum sample from MDS patient no. 20, (Additional
file 2: Table S2), a breast cancer serum sample (sample
no. 37, Additional file 2: Table S3), a prostate cancer
sample (sample no. 28, Additional file 2: Table S4) and a
blood-donor sample (no. 29, Additional file 2: Table S1)
were analyzed using size-exclusion chromatography. In
the MDS sample, TK1 activity appeared in two peaks,
one in the MW range of 400-720 kDa and the other in
the MW range 50-200 kDa (Figure 6A). A TK1 polypep-
tide of 25 kDa was also observed in two peaks, similar to
TK1 activity, however, in this experiment, the TK1 protein
Figure 5 Serum TK1 activity, STK1 protein levels and STK1 specific activities in different groups. (A) STK1 activities in sera from blood
donors (•), MDS (■), breast (▲) and prostate cancer patients (▼). (B) STK1 protein levels in sera from blood donors (•), MDS (■), breast (▲) and
prostate cancer patients (▼). (C) Specific activities of TK1 in sera from blood donors (•), MDS (■), breast (▲) and prostate cancer patients (▼).
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tions (Figure 6B, Additional file 1: Figure S5A). In
serum from the breast cancer patient, 90% of total TK1
activity eluted in fractions corresponding to MWs of
300-720 kDa (Figure 6C) with two minor peaks ob-
served in the MW range 200-50 kDa. However, the im-
munoaffinity/Western blotting analysis revealed a TK1
polypeptide of 25 kDa in almost all fractions (Figure 6D)
with no apparent correlation between band intensity




Tumor type N Mean ± SD Ran
MDS 22 136 ± 112 30 -
Breast cancer 42 79 ± 69 12 -
Prostate cancer 47 62 ± 47 11 -
Blood donors 30 130 ± 62 29 -
*indicates the significant difference levels (* = low, ** = medium, *** = high).serum from a prostate cancer patient, very low TK1 ac-
tivity levels were noted in fractions corresponding to
the MW range 200-720 kDa (Figure 6E). However, the
TK1-25-kDa protein showed a peak in fractions corre-
sponding to MWs of 200-40 kDa. There was also a low
level of 25-kDa protein in the high-MW fractions
where a TK1 activity peak was observed (Figure 6F). In
the sample from the blood donor, a TK1 activity peak
eluted in the high-MW region (Figure 6G), and no pro-
tein bands were detected (data not shown).ity values in different groups and comparison with
ge (nmol/min/mg) Comparison with
blood donors
P value
515 no signifcant difference 0.635
268 Yes (***) 0.0005
183 Yes (***) <0.0001
243
Figure 6 Molecular forms of serum TK1 analyzed using size-exclusion chromatography. (A) Thymidine kinase 1 activity in serum fractions
from an MDS patient. (B) Western blotting analysis of MDS serum fractions using the immunoaffinity method. (C) Thymidine kinase 1 activity in
serum fractions from a patient with breast cancer. (D) Western blotting analysis of serum fractions from a patient with breast cancer using the
immunoaffinity method. (E) Thymidine kinase 1 activity in serum fractions from a patient with prostate cancer. (F) Western blotting analysis of
serum fractions from a prostate cancer patient using the immunoaffinity method. (G) Thymidine kinase 1 activity in fractions from the serum of a
blood donor. The numbers denote FPLC fractions. Arrows denote the elution position with respect to molecular weight markers.
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multiple oligomeric forms and that TK1 activity was as-
sociated with the very high MW complexes, whereas
TK1 protein was noted in many different molecular
forms (from 40-700 kDa), with no apparent correlation
to TK1 activity peaks. These experiments were repeated
using serum samples from one additional MDS (sample
no. 15), breast cancer (sample no. 20) and prostate can-
cer (sample no. 27) patient and a blood donor (sample
no. 17), and in general, very similar results were ob-
served, as shown in Additional file 1: Figure S4. There-
fore, we consider the different distributions in TK1
activity and TK1 protein levels described above for
MDS, breast and prostate patients as being representa-
tive for the respective patient groups.
Discussion
Serum TK1 activity measurement has been used as
tumor proliferation marker for the diagnosis and prog-
nosis of various hematological malignancies [11,12] and
in some solid-tumor diseases [8,15]. Development of
TK1 antibody-based methods demonstrated that the
concentration of STK1 protein may be used for the
prognosis and monitoring of tumor therapy in severaltypes of solid tumor diseases [19,21,23,36]. In this
study, we attempted to clarify the reasons underlying
the apparently different information in different forms
of malignant diseases that measurement of STK1 activ-
ities and TK1 protein levels provide. We took advan-
tage of the fact that we have sensitive assays for
determining STK1 activities and STK1-25-kDa protein
levels. Thus far, no studies have been conducted where
the specific activities of STK1 or the molecular forms
of TK1 in different types of tumor diseases have been
analyzed in detail.
Patients with myelodysplastic syndrome (MDS) are
classified into many subtypes but all have a dysfunctional
blood-forming capacity, more specifically in regeneration
of myeloid linages, with a large fraction of patients pro-
gressing to acute myeloid leukemia. In the patients
tested here, increased STK1 activities and 25 kDa pro-
tein, above the cut-off (12.5 ng/mL) of the blood donor
control group, was observed in 15 out of 22 cases. This
number is surprisingly high, particularly because the
control group was not age-matched and was of a mean
age of 27 compared with the mean age of 76 y in the
MDS group. Earlier studies have shown a decrease in
mean STK1 activity and protein levels with increasing
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tients varied from 30 to 858 nmoles per min per mg TK
25 kDa protein; however, the mean value was similar to
that of the blood donor group. The mechanism for the
variation and similarities between blood donors and
MDS patients in specific activities and molecular form
will be discussed below. Here, we have studied 111 clin-
ical samples from patients who were diagnosed with
MDS, breast or prostate cancer. Particularly in breast
cancer patients, the availability of clinical data on staging
and histological grad enabled comparisons between the
two assays. Similarly, Gleason scores (GS) of the prostate
cancer patients made a preliminary clinical assessment
of the STK1 protein assay possible. Furthermore, these
results indicate that the STK1 protein assay may distin-
guish early stages of cancer diseases more efficiently
compared with the TK activity assay. The principles and
basic performance of the two STK1 assays used here
have been described previously [9,25].
Consistent with earlier studies using TK-Liaison and
Divitum TK activity assays [37], we observed that STK1
activity values in sera from breast and prostate cancer
were higher than the healthy cut-off in approximately
25% of samples. This finding was also evident from our
ROC curve analysis, which showed a sensitivity of 26%
with 96% specificity in the case of breast cancer. How-
ever, with respect to STK1 protein levels, immunoaffin-
ity/Western blotting assays distinguished breast cancer
from blood donors with sensitivity close to 79%at 96%
specificity. In the case of prostate cancer patients, the re-
sults were similar, with the STK1 protein assay improv-
ing sensitivity 3-fold compared with the activity assay.
Previous studies demonstrated that in sera from patients
with leukemia, gastric and breast cancer and healthy
controls, there was a significant correlation between
TK1 protein concentration and TK1 activity [24]. Similar
results were found in this study, and a possible explan-
ation for these correlations may be that the protein assay
measures both active and inactive serum TK1, whereas
the activity assay measures only the active high-MW
TK1 protein complexes. The results presented here are
consistent with our recently published results on STK1
determination in dogs with malignant diseases. We ob-
served no significant difference in STK1 activities in sera
from dogs with solid tumors compared with healthy
dogs. However, there was a significant difference in
STK1 protein levels between these two groups [25]. Al-
though the clinical application of TK1 as a biomarker
has increased in recent years, very few studies have been
conducted to determine the molecular forms of TK1 in
different forms of malignancies [32,33]. Here, we used
size-exclusion chromatography to investigate this ques-
tion. The most significant and unexpected finding was
that serum TK1 activity and TK1 protein did not clearlyco-elute in any of the sera analyzed from patients with
malignancies. The situation in blood donors was not re-
solved due to the fact that TK1 protein was not detected
in the fractions containing enzyme activity. Sera from
MDS patients showed two peaks of TK1 activity and the
TK1 protein; however, the patterns were not identical.
The discrepancies between TK1 activity and protein-
elution profiles were even more apparent in sera from
breast and prostate cancer patients, where STK1 activity
was primarily observed as an active high-MW complex,
whereas the TK1 polypeptide was observed in almost all
serum fractions in breast cancer. In sera from prostate
cancer patients, the majority of TK1 protein eluted with
a peak at approximately 100 kDa, and only a minor frac-
tion eluted in the high-MW form. These results strongly
suggest that serum TK1 is present in many oligomeric
forms containing both active and inactive TK1 protein.
The high-MW oligomers apparently have a higher pro-
portion of active TK1 protein compared with those with
lower molecular weights. The results clearly show that
there is a larger fraction of inactive TK1 protein in sera
from breast and prostate cancer patients; however, even
in this case, there is apparently a mixture of both active
and inactive TK1 in the fractions, thus explaining the
lack of co-elution between TK1 activity and protein. The
varying compositions of the TK1 oligomers in sera from
different patients may also explain the differences in spe-
cific activities of TK1 observed in sera from blood do-
nors and MDS patients compared with those in sera
from breast or prostate cancer patients. Specific activity
indicates the active enzyme in a particular concentration
of protein. To determine the specific activity of TK1 in
different malignancies, both STK1 activity and TK1 sub
unit of 25 kDa protein levels were measured in clinical
samples. In the MDS sera, STK1 activity follows the
STK1 protein profile, but there was no complete correl-
ation between the activity and 25 kDa protein in all frac-
tions (Additional file 1: Figure S5A). In case of healthy,
there was only one peak in a high MW complex form
and we could not observe any protein bands in the west-
ern blot analysis, indicating that the protein levels were
very low in the fractions. These results indicate that TK1
elution profile based on TK1 activity or TK1 protein are
similar and that most of the TK1 oligomers are active,
resulting in high specific activity (active TK1/ mg of TK1
25 kDa protein). Whereas in breast and prostate cancer
sera, the TK1 elution profile was different and the TK1
activity eluted as a major peak with high MW, while the
TK1 protein eluted in multimeric forms with different
MW, representing both active and inactive forms of TK1
(Additional file 1: Figure S5B and S5C). A recent study
was done on comparison of TK1 molecular forms in sera
from healthy dogs, dogs with leukemia and mammary
tumors. The results showed that TK1 exits as high MW
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sera. TK1 protein also follows the similar pattern in both
cases. However, in mammary tumor sera, TK1 activity
eluted as a major peak with high MW complex, while
the TK1 protein eluted in multimeric forms with differ-
ent MW, representing both active and inactive forms of
TK1 [38]. These results are similar to that what we ob-
served in human TK1 forms in different sera. These
differences in molecular forms lead to lower specific
activity as shown in Table 2. These findings are most
likely due to modifications of TK1 in sera from pa-
tients with different cancer diseases. Attempts to de-
fine these presumed structural differences are ongoing
and may lead to the development of an in vitro diag-
nostic test specific for serum TK1 in patients with dif-
ferent tumor diseases.
Conclusions
Methods based on anti-TK1 antibodies and 3H-dThd
phosphorylation for determining the specific activity of
serum TK1 strongly indicate that there is a large fraction
of inactive TK1, particularly in sera from patients with
breast and prostate cancer. The results shown here
strongly indicate that STK1 protein assays are more sen-
sitive for the detection of early stages of breast and pros-
tate cancer compared with STK1 activity measurements.
Size-exclusion analysis of the molecular forms of STK1
demonstrated that more active forms of STK1 are found
as high-molecular-weight oligomers whereas more in-
active forms of STK1 protein are found as intermediate
and low-molecular-weight complexes. This information
is important for the future development of TK1 assays,
which are more efficient for detecting early stages of
common tumor diseases.
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